Microbia leads with a massive $75M round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Microbia
|
$75M
|
Sigma Capital Management, Jennison Associates and Maverick Capital |
An anti-constipation pill is now in a mid-stage trial and a cholesterol-blocking pill is in an early-stage study. |
|
Neuromed Pharmaceuticals
|
$25M
|
MPM Capital |
Neuromed will use the funds to advance its lead program for developing calcium channel blockers for chronic pain. |
|
Nereus Pharmaceuticals
|
$18.3M
|
HBM BioVentures and HBM BioCapital LP |
The tranche was triggered by the company's success at hitting milestones in its drug development work. |
|
ARCA Discovery
|
$15M
|
Atlas Venture |
This round of financing allows ARCA to complete the filing of an NDA for bucindolol, a genetically-targeted cardiovascular drug. |
|
Ikonisys
|
$10M
|
Trevi Health Ventures |
Ikonisys expects to advance its prenatal diagnostics program to FDA submission and further develop its oncology program. |
|
Cytomics Systems
|
€10M
|
Edmond de Rothschild Investment Partners and Truffle Venture |
This round will enable the company to accelerate the development of its most advanced antifungal compounds. |